AGWCA
HAE icon

Annis Gardner Whiting Capital Advisors’s Haemonetics HAE Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
2,890
+2,659
+1,151% +$171K 0.03% 330
2026
Q1 		$13K Hold
231
– – ﹤0.01% 826
2025
Q4 		$18.5K Hold
231
– – ﹤0.01% 670
2025
Q3 		$11.3K Buy
231
+43
+23% +$2.66K ﹤0.01% 692
2025
Q2 		$14K Hold
188
– – ﹤0.01% 635
2025
Q1 		$11.9K Hold
188
– – 0.01% 523
2024
Q4 		$14.7K Hold
188
– – ﹤0.01% 486
2024
Q3 		$15.1K Buy
188
+46
+32% +$3.72K ﹤0.01% 503
2024
Q2 		$11.7K Hold
142
– – ﹤0.01% 663
2024
Q1 		$12.1K Buy
+142
New +$11.1K ﹤0.01% 643

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's HAE Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors increased its Haemonetics (HAE) stake by 1,151% in Q2 2026, buying an estimated $171K and bringing the position to 2,890 shares worth $217K. The position accounts for 0.03% of the portfolio, ranked #330.

Annis Gardner Whiting Capital Advisors first reported a position in HAE in Q1 2024 and has held it in 10 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors held 2,890 shares of Haemonetics worth $217K as of Q2 2026.
  • Annis Gardner Whiting Capital Advisors bought 2,659 Haemonetics shares in Q2 2026, an estimated $171K.
  • Haemonetics made up 0.03% of Annis Gardner Whiting Capital Advisors's portfolio in Q2 2026, its #330 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Haemonetics in Q1 2024 and has held it in 10 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.